MedPath

Levothyroxine

Generic Name
Levothyroxine
Brand Names
Eltroxin, Ermeza, Euthyrox, Levo-T, Levothroid, Levoxyl, Np Thyroid, Synthroid, Thyquidity, Tirosint, Unithroid
Drug Type
Small Molecule
Chemical Formula
C15H11I4NO4
CAS Number
51-48-9
Unique Ingredient Identifier
Q51BO43MG4
Background

Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T (tetraiodothyronine or thyroxine) and T (triiodothyronine or Liothyronine), resulting in diminished down-stream effects of these hormones. Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop such as fatigue, increased heart rate, depression, dry skin and hair, muscle cramps, constipation, weight gain, memory impairment, and poor tolerance to cold temperatures.

In response to Thyroid Stimulating Hormone (TSH) release by the pituitary gland, a normally functioning thyroid gland will produce and secrete T, which is then converted through deiodination (by type I or type II 5′-deiodinases) into its active metabolite T. While T is the major product secreted by the thyroid gland, T exerts the majority of the physiological effects of the thyroid hormones; T and T have a relative potency of ~1:4 (T4:T3). T and T act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. As a result, many cardiac functions including heart rate, cardiac output, and systemic vascular resistance are closely linked to thyroid status.

Prior to the development of levothyroxine, Thyroid, porcine or desiccated thyroid, used to be the mainstay of treatment for hypothyroidism. However, this is no longer recommended for the majority of patients due to several clinical concerns including limited controlled trials supporting its use. Desiccated thyroid products contain a ratio of T4 to T3 of 4.2:1, which is significantly lower than the 14:1 ratio of secretion by the human thyroid gland. This higher proportion of T3 in desiccated thyroid products can lead to supraphysiologic levels of T3 which may put patients at risk of thyrotoxicosis if thyroid extract therapy is not adjusted according to the serum TSH.

Indication

Levothyroxine is indicated as replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. It is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Associated Conditions
Edematous Fibrosclerotic Panniculopathy (Cellulite), Hypothyroidism, Localized Adiposity, Myxedema coma, Euthyroid Goitre, Thyrotropin dependent Well-Differentiated Thyroid Cancer

The Effects of T4 Versus T4/T3 on Psychological Distress After Total Thyroidectomy in Thyroid Cancer Patients

Not Applicable
Completed
Conditions
Depression
Anxiety
Fatigue
Distress
Thyroid Cancer
Interventions
Drug: Comthyroid
First Posted Date
2017-01-18
Last Posted Date
2019-02-22
Lead Sponsor
Inje University
Target Recruit Count
150
Registration Number
NCT03024151
Locations
🇰🇷

Dongsik Bae, Busan, Korea, Republic of

🇰🇷

Dong sik Bae, Busan, Korea, Republic of

Hypothyroidism, Metabolism and Food Intake

Completed
Conditions
Hypothyroidism
Interventions
First Posted Date
2016-12-15
Last Posted Date
2018-11-06
Lead Sponsor
Herlev Hospital
Target Recruit Count
18
Registration Number
NCT02993562
Locations
🇩🇰

Center for Diabetes Research, Herlev and Gentofte Hospitals, Copenhagen, Region Hovedstaden, Denmark

Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy

Phase 4
Terminated
Conditions
Thyroid Cancer
Postsurgical Hypothyroidism
Interventions
First Posted Date
2016-10-27
Last Posted Date
2020-12-01
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
14
Registration Number
NCT02946918
Locations
🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.

Phase 1
Completed
Conditions
Healthy
Diabetes
Interventions
First Posted Date
2016-09-30
Last Posted Date
2017-12-14
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
45
Registration Number
NCT02920385
Locations
🇩🇪

Novo Nordisk Investigational Site, Berlin, Germany

Randomized Crossover Trial for the Evaluation of the Possible Effects in the Intestine of Two Different Pharmaceutical Forms of L - Thyroxine in Patients With Primary Acquired Hypothyroidism

First Posted Date
2016-09-28
Last Posted Date
2016-09-28
Lead Sponsor
Meyer Children's Hospital IRCCS
Target Recruit Count
70
Registration Number
NCT02917863
Locations
🇮🇹

Meyer Children's Hospital, Florence, Italy

Hypothyroidism, Metabolism and Quality of Life - Focus on QOL, REE, Cognitive Function and Body Composition

Completed
Conditions
Hypothyroidism
Interventions
First Posted Date
2016-09-07
Last Posted Date
2018-08-01
Lead Sponsor
Herlev Hospital
Target Recruit Count
42
Registration Number
NCT02891668
Locations
🇩🇰

Department of internal Medicine, Herlev Hospital, Herlev, Region Hovedstaden, Denmark

The TRUST Study - CardioVascular Imaging IMT

Phase 4
Completed
Conditions
Thyroid Dysfunction
Atherosclerosis
Heart Failure
Interventions
Drug: Placebo
First Posted Date
2016-07-14
Last Posted Date
2017-02-28
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Target Recruit Count
184
Registration Number
NCT02832934
Locations
🇨🇭

Department of General Internal Medicine, Lausanne, Vaud, Switzerland

🇨🇭

Clinic for General Internal Medicine, Bern University Hospital Bern, Bern, Switzerland

🇨🇭

Cardiology Division, Geneva University Hospitals, Geneva, Switzerland

The TRUST Trial - CardioVascular Imaging ECHO

Phase 4
Completed
Conditions
Atherosclerosis
Thyroid Dysfunction
Heart Failure
Interventions
Drug: Placebo
First Posted Date
2016-07-14
Last Posted Date
2017-02-28
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Target Recruit Count
185
Registration Number
NCT02832960
Locations
🇨🇭

Clinic for General Internal Medicine, Bern University Hospital Bern, Bern, Switzerland

🇨🇭

Cardiology Division, Geneva University Hospitals, Geneva, Switzerland

🇨🇭

Department of General Internal Medicine, Lausanne, Vaud, Switzerland

Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding

Phase 4
Withdrawn
Conditions
Hypothyroidism
Interventions
First Posted Date
2015-10-16
Last Posted Date
2021-09-22
Lead Sponsor
Jocelyne Karam
Registration Number
NCT02577367
Locations
🇺🇸

Maimonides Medical Center, Brooklyn, New York, United States

Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?

Terminated
Conditions
Hypothyroidism
Postsurgical Hypothyroidism
Interventions
First Posted Date
2015-10-05
Last Posted Date
2023-06-08
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
12
Registration Number
NCT02567877
Locations
🇺🇸

University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

© Copyright 2025. All Rights Reserved by MedPath